VAX014

DRUG2 trials

Sponsors

Vaxiion Therapeutics

Conditions

Advanced Solid TumorAdvanced Solid Tumors Appropriate for Treatment With Either Nivolumab or PembrolizumabUrothelial Carcinoma of the Urinary Bladder

Phase 1

A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer

CompletedNCT03854721

Vaxiion TherapeuticsUrothelial Carcinoma of the Urinary Bladder

Start: 2019-05-10End: 2023-03-01Updated: 2023-03-03

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

RecruitingNCT05901285

Vaxiion TherapeuticsAdvanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab

Start: 2023-11-02End: 2027-11-01Target: 48Updated: 2026-08-24

Related Papers

VAX014 for instillation in subjects with nonmuscle-invasive bladder cancer.

Journal of Clinical Oncology2022-02-165 citations